Delving into the Latest Updates on Antivirals (Global Biotech) with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

antivirals (Global Biotech), KOV

Target

DNA polymerase x RT

Action

inhibitors

Mechanism

DNA polymerase inhibitors(DNA polymerase inhibitors), RT inhibitors(Viral reverse transcriptase inhibitors)

Therapeutic Areas

Immune System DiseasesInfectious DiseasesUrogenital Diseases

Active Indication-

Inactive Indication

HIV Infections

Originator Organization

Global Biotech Inc.

Active Organization-

Inactive Organization

Global Biotech Inc.

License Organization-

Drug Highest PhasePendingDiscovery

First Approval Date-

Regulation-

Clinical decision support systems (CDSSs) are increasingly developed to improve healthcare delivery. To update the last review on this topic, we conducted a narrative review aimed at describing all CDSSs identified through searches of Medline dedicated to antimicrobials prescribing from 2019 to 2023. All original research describing a CDSS dedicated to antimicrobials selection, including antibiotics, antivirals, antifungals, and antiparasitic drugs, were eligible. CDSS goals and their potential clinical impacts, as well as characteristics of studies for CDSS evaluation (type of study, population, setting, objectives, and main findings) were extracted. Among the 28 studies included, most (N = 24) were dedicated to antibiotics and 15 were embedded in an electronic health record. Only one CDSS was developed in low- and middle-income countries (LMICs). The main goal of the included CDSSs was to assist clinicians in the selection of antimicrobials. Ten studies included more than 1000 patients or prescriptions, and most of them were implemented in hospitals. Only six studies reported no impact of CDSSs on antibiotic use or compliance with guidelines. CDSSs dedicated to antimicrobial prescribing is an area of increasing activity, with solutions offering the potential to optimize antimicrobial use. Although there is an urgent need to develop CDSSs, CDSS clinical evaluation appears to be an important requirement before implementation. Special efforts are needed to ensure transferability of CDSSs and high adoption, especially in LMICs, while improving awareness through education and training.

01 Aug 2025·LARYNGOSCOPE

Evaluating Treatment Patterns in Bell's Palsy Using Nationwide Employer‐Sponsored Healthcare Claims

Article

Author: Elkersh, Yehia ; Ratna, Sujay ; Gray, Mingyang ; Rosenberg, Joshua ; Agarwal, Parul ; Edalati, Shaun

ABSTRACT:

Objective:

Professional society guidelines provide clear recommendations regarding the use of high‐dose steroids and/or antiviral therapy for Bell's palsy patients. This study evaluates national trends in the care of Bell's palsy patients and identifies current treatments.

Methods:

A retrospective cohort study of adult Bell's palsy patients was conducted using ICD‐9‐CM and ICD‐10‐CM diagnosis codes from 2013 to 2020. These patients were continuously enrolled in the employer‐sponsored MarketScan commercial or Medicare outpatient and prescription drug claims data for at least 1 year. The main outcome of interest was prescription rates of high‐dose steroids and antivirals after the diagnosis date.

Results:

In this cohort of 66,708 adult Bell's palsy patients, 29,824 (44.7%) received no treatment. 22,736 (34.1%) received combination therapy, 11,866 (17.8%) received steroids only, and 2282 (3.4%) received antivirals only. Males were more likely to receive combination therapy. 51.9% of Bell's palsy patients in this cohort received the AAO‐recommended treatment of steroids within 72 h of diagnosis. Patients in the Southern and Western United States were more commonly prescribed combination therapy. Comorbidities such as cerebrovascular disease and symptoms like ear pain were associated with a higher likelihood of receiving combination therapy. Treatment initiation, particularly for steroids, occurred on the index date, first insurance claim, in 94.56% of cases.

Conclusion:

Only 51.9% of Bell's palsy patients in this cohort received the AAO‐recommended treatment with high‐dose steroids with or without antiviral therapy. This research provides valuable insights into the real‐world management of Bell's palsy, emphasizing the need for adherence to established treatment guidelines.

Level of Evidence:

N/A

01 Jul 2025·INTERNAL MEDICINE JOURNAL

Clinical characteristics and treatment of varicella zoster virus central nervous system infection in an Australian tertiary hospital

Article

Author: Sasadeusz, Joe ; Yan, Terry ; Lam, Connie ; Chen, Eve ; Thevathasan, Arthur ; Muhi, Stephen ; Moso, Michael

Abstract:

Background and Aim:

Varicella zoster virus (VZV) is a neurotropic herpesvirus. With improved access to molecular diagnostics, there is increasing recognition of VZV with central nervous system involvement. This study aimed to describe the demographic, clinical and treatment characteristics of patients admitted to an Australian tertiary hospital with VZV central nervous system infection.

Methods:

Retrospective study of all adult patients (aged ≥18 years) presenting to an Australian tertiary hospital between November 2010 and May 2023 with a clinical syndrome of or imaging consistent with meningitis or encephalitis and detectable VZV DNA in cerebrospinal fluid using polymerase chain reaction.

Results:

There were 48 cases of VZV meningitis and 13 cases of VZV encephalitis identified during the study period. The median age of patients with VZV meningitis and encephalitis was 34 years (range 21–86 years) and 73 years (range 22–94 years) respectively. All patients with VZV encephalitis and 37 of 48 (77.1%) with meningitis received intravenous (IV) acyclovir. Eight patients with VZV meningitis were treated with oral antivirals alone and seven were managed without antivirals or with ≤48 h of empiric antiviral therapy only; none of these patients experienced an adverse clinical outcome. Two patients with VZV encephalitis died. Seven patients experienced neurological complications, three with VZV meningitis and four with VZV encephalitis. Age and length of stay were associated with adverse clinical outcomes.

Conclusion:

VZV encephalitis predominates in older patients while VZV meningitis predominates in younger patients. IV acyclovir remains the standard of care for treatment of VZV encephalitis; however, its role in VZV meningitis is less clear. Controlled trials should be conducted to inform its use, particularly in low‐risk patients with VZV meningitis.

100 Deals associated with Antivirals (Global Biotech)

Login to view more data